Current pharma model “not sustainable” during COVID-19, says...
At eyeforpharma Daiichi Sankyo’s Manuel Reiberg spoke about why the industry should look to make drugs more affordable in the wake of the COVID-19 pandemic and “leave the next generation a healt
